Xiao-Dong Jiao
Overview
Explore the profile of Xiao-Dong Jiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hui J, Yan H, Ding S, Qin B, Jiao X, Zang Y
Cancer Control
. 2025 Feb;
32:10732748251320822.
PMID: 39938068
Background: This cohort study aimed to evaluate the impact of tumor burden (TB) on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). Materials And Methods:...
2.
Sun S, Jiao X, Chen Z, Cao Q, Zhu J, Shen Q, et al.
Nat Commun
. 2024 Aug;
15(1):6640.
PMID: 39103324
Immune checkpoint inhibitor (ICI)-induced myocarditis involves intensive immune/inflammation activation; however, its molecular basis is unclear. Here, we show that gasdermin-E (GSDME), a gasdermin family member, drives ICI-induced myocarditis. Pyroptosis mediated...
3.
Qin B, Jiao X, Yuan L, Wu Y, Ling Y, Zang Y
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38631713
No abstract available.
4.
Duan X, Qin B, Jiao X, Liu K, Wang Z, Zang Y
Signal Transduct Target Ther
. 2024 Mar;
9(1):57.
PMID: 38438349
In the era of precision medicine, it has been increasingly recognized that individuals with a certain disease are complex and different from each other. Due to the underestimation of the...
5.
Qin B, Jiao X, Wang Z, Liu K, Wu Y, Ling Y, et al.
Int J Cancer
. 2023 May;
153(4):815-825.
PMID: 37155342
The combination of immunotherapy and antiangiogenic agents for the treatment of refractory solid tumor has not been well investigated. Thus, our study aimed to evaluate the efficacy and safety of...
6.
Jiao X, Qin B, Wang Z, Liu K, Wu Y, Ling Y, et al.
Front Oncol
. 2023 Mar;
13:860711.
PMID: 36910668
Purpose: We evaluated he effects of molecular guided-targeted therapy for intractable cancer. Also, the epidemiology of druggable gene alterations in Chinese population was investigated. Materials And Methods: The Long March...
7.
Wang L, Chen S, Zhong X, Jiao X, Liu K, Qin B, et al.
Anticancer Drugs
. 2023 Feb;
34(10):1146-1150.
PMID: 36728908
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) dramatically improve the clinical outcomes of non-small cell lung cancer (NSCLC) patients harboring EGFR -sensitive mutations. Despite the remarkable efficacy...
8.
Duan X, Liu K, Jiao X, Qin B, Li B, He X, et al.
Front Oncol
. 2023 Jan;
12:1007146.
PMID: 36686739
Background: Tumor mutation burden (TMB) is a promising biomarker positively associated with the benefit of immunotherapy and that might predict the outcome of chemotherapy. We described the prognostic value of...
9.
Yang B, Deng B, Jiao X, Qin B, Lu Y, Zhang W, et al.
Cell Oncol (Dordr)
. 2022 Oct;
45(6):1297-1309.
PMID: 36260222
Purpose: Our study intended to explore how low-dose anti-angiogenic drugs affected anti-tumor immunity of tumor-infiltrating exhausted CD8T cells and achieved better clinical response when combined with immunotherapy. We set out...
10.
Qin B, Jiao X, Wang Y, Wu Y, Ling Y, Liu K, et al.
Lung Cancer
. 2022 Jun;
170:91-97.
PMID: 35728482
Background: The types of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients who could obtain significant clinical benefit from the dual inhibition of EGFR/vascular EGFR (VEGFR) pathways remain...